With the maturity of theory and technology, the usage range of PD-1/PD-L1 blockade has gradually expanded, including metastatic nonsquamous NSCLC, advanced RCC, unresectable or metastatic, recurrent HNSCC, MSI-H/dMMR CRC, relapsed or refractory classical Hodgkin lymphoma (cHL), locally advanced or metastatic urothelial carcinoma, cervical cancer, gastric cancer, and esophageal cancer (Ansell et al., 2015; Beckermann et al., 2017; Chae et al., 2018; Lin et al., 2018; Saito et al., 2018; Oliveira et al., 2019; Wang and Li, 2019; Nassar et al., 2020; Wu et al., 2020). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.